Zhaoke Ophthalmology Limited
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People's Republic of China, South Korea, Hong Kong, and internationally. It develops various drugs that cover ophthalmic indications, including dry eye disease, myopia, presbyopia, wet age-related macular … Read more
Zhaoke Ophthalmology Limited (9FX) - Total Liabilities
Latest total liabilities as of June 2025: €362.61 Million EUR
Based on the latest financial reports, Zhaoke Ophthalmology Limited (9FX) has total liabilities worth €362.61 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhaoke Ophthalmology Limited - Total Liabilities Trend (2021–2024)
This chart illustrates how Zhaoke Ophthalmology Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhaoke Ophthalmology Limited Competitors by Total Liabilities
The table below lists competitors of Zhaoke Ophthalmology Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Maui Land & Pineapple Company Inc
NYSE:MLP
|
USA | $12.12 Million |
|
Varia US Properties Ltd
SW:VARN
|
Switzerland | CHF840.43 Million |
|
DURCF
PINK:DURCF
|
USA | $177.05 Million |
|
Shenzhen Capol International & Associates Co Ltd
SHE:002949
|
China | CN¥1.34 Billion |
|
Vishnu Chemicals Limited
NSE:VISHNU
|
India | ₹8.27 Billion |
|
Hube Yangfan Holding Co Ltd
SHG:600421
|
China | CN¥166.75 Million |
|
Jiangsu Jingxue Insulation
SHE:301010
|
China | CN¥671.07 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Zhaoke Ophthalmology Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhaoke Ophthalmology Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhaoke Ophthalmology Limited (2021–2024)
The table below shows the annual total liabilities of Zhaoke Ophthalmology Limited from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €343.44 Million | -7.68% |
| 2023-12-31 | €372.02 Million | +67.39% |
| 2022-12-31 | €222.25 Million | +102.19% |
| 2021-12-31 | €109.92 Million | -- |